From what I can tell, the January 2006 Barron's Roundtable was published on / around January 16. So the prices quoted are stale by 1-2 weeks. Still, interesting that most of Giroux's picks have done well since he recommended them. I've had good success with CNP. Today, I briefly considered adding KDP and SBUX, but both are substantially higher, so passed. Posted for what value or insights it might provide. Haven't followed others' '26 recommendations. But Mario Gabelli is another I've gotten insights from in past years, Sold MSGS too early around year-end after a 25% short-term gain. Hanging on to another of his picks, BATRA.
Giroux's Picks Ticker Price 1/2/26
Keurig Dr Pepper / KDP $27.73
Cytokinetics / CYTK 61.73
Arcellx / ACLX 63.34
Apogee Therapeutics / APGE 75.78
Vaxcyte / PCVX 46.46
Dyne Therapeutics / DYN 18.50
BioNTech / BNTX 96.69
Starbucks / SBUX 83.97
NiSource / NI 42.16
CenterPoint Energy / CNP 38.73
Becton Dickinson / BDX 194.94
Added - PRWCX is languishing a bit YTD. - 0.56% according to M* yesterday. And sacrilege - 1 or 2 posters have reported selling the fund in recent weeks. While I haven't owned the fund for several years, I admire Giroux's smarts & success. My only real gripe was the ballooning size of the AUM at the time I last owned it.
Comments
shifted most trp $ to prcfx. maybe someday they will take advantage of its ~100x lower aum for better downcap picks.
anyone expect to see buys in garp software?
Doesn't that just grab ya? I've bought some of their gold rated funds and remained very satisfied few months or a year later when they dropped the rating to neutral. A fund can't be "all things to all people." They seem to penalize former gold or silver rated funds that lose a bit of performance lead over the pack. I continue to like CPLSX as a conservative offering (dropped from gold to neutral). And they did the same thing to LCORX - for no good reason that I can tell.
Morningstar Ratings
Seems he did not let this winner run.
?? i would not be surprised if giroux realized >10-bagger in GE !
even then he admitted it was a more a chance on culp than his usual hard numbers GARP process.
regardless, no GE investor used leverage to outpace culp's personal return, and probably never will.
My May 2020 MFO post regarding PRWCX and GE :
https://mutualfundobserver.com/discuss/discussion/56112/prwcx-position-in-ge
Not sure when PRWCX sold its GE positions. Back Testing (GE, GEV, and GEHC) since (April 2024).
GE has had a 36.5% annualized return
GEV has had a 149% annualized return
GEHC has had a (-7.2%) annualized return
https://portfoliovisualizer.com/backtest-portfolio?s=y&sl=3sWUfVCzbFOYjxGWjep3eg